By vgreene, 10 October, 2020 Drugs under investigation include casirivimab REGN10933 imdevimab REGN10987 bamlanivimab LY CoV555 etesevimab LY CoV016 sotrovimab VIR 7831
By vgreene, 10 October, 2020 Proposed mechanism: binds to specific viral targets and acts as neutralizing antibodies; most agents target spike protein, preventing viral entry and replication
By vgreene, 10 October, 2020 See <a href=https://clinicaltrials.gov/ct2/results?cond=&term=covid+convalescent+plasma&cntry=&state=&city=&dist=&Search=Search><b><u>all convalescent plasma trials</u></b></a>, including international
By vgreene, 10 October, 2020 See <a href=https://clinicaltrials.gov/ct2/results?cond=&term=covid+convalescent+plasma&cntry=US&state=&city=&dist=><b><u>U.S. convalescent plasma trials</u></b></a>
By vgreene, 10 October, 2020 Treatment With Convalescent Plasma for COVID-19 Patients in Wuhan, China; <a href=https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25882><b><u>full-text <i>J Med Virol</i> article</u></b></a>
By vgreene, 10 October, 2020 Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection; <a href=https://journal.chestnet.org/article/S0012-3692(20)30571-7/fulltext><b><u>full-text <i>CHEST</i> article</u></b></a>
By vgreene, 10 October, 2020 Factors Associated With Good Patient Outcomes Following Convalescent Plasma in COVID-19: A Prospective Phase II Clinical Trial; <a href=https://link.springer.com/article/10.1007/s40121-020-00341-2><b><u>full-text <i>Infect Dis Ther</i> article</u></b></a>
By vgreene, 10 October, 2020 Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients; <a href=https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa228/5826985><b><u>full-text <i>J Infect Dis</i> article</u></b></a>
